Neurodegeneration is a gradual decay process leading to the depletion of neurons in both
the central and peripheral nervous systems, ultimately resulting in cognitive dysfunctions …

Drug discovery is a generally inefficient and capital-intensive process. For
neurodegenerative diseases (NDDs), the development of novel therapeutics is particularly …

Background Phosphodiesterase-5 inhibitors (PDE5i) have been evaluated as a novel
treatment for Alzheimer's disease and related dementias (ADRD), but two recent cohort …

Poly (ADP-ribose) polymerase (PARP) plays a key role in repairing DNA damage, and
several PARP inhibitors have been approved as treatments in BRCA1/2 mutated breast and …

Backgound Gallic acid (GA) is a polyphenolic substance which can be sourced naturally
from plant sources and can also be synthesized industrially. In-depth study on GA in recent …

As the world population ages, there will be an increasing need for effective therapies for
aging‐associated neurodegenerative disorders, which remain untreatable. Dementia due to …

Alzheimer's disease (AD) remains a significant challenge in the field of neurodegenerative
disorders, even nearly a century after its discovery, due to the elusive nature of its causes …

The spectrum of neurodegenerative diseases known today is quite extensive. The
complexities of their research and treatment lie not only in their diversity. Even many years of …

BACKGROUND: People with advanced Alzheimer's disease tend to be sedentary and
passive unless staff intervene to support their occupation. OBJECTIVE: This pilot study …

Drug discovery is a tedious process that takes a long time and high cost, while reverse
pharmacology is a target-based procedure, which depends mainly on identifying the …